January 09, 2025

curATime is looking for partners!

curATime is looking for partners!
Go back

The curATime cluster is one of 14 pioneering “Clusters4Future” initiatives funded by the German Federal Ministry of Education and Research (BMBF). Its mission is to promote personalized approaches to combat atherothrombosis-related diseases and to establish the Rhine-Main-Palatinate region as an international driver of innovation.

For the planned second implementation phase, the cluster is seeking new partners from science and industry who share its passion for revolutionary research in the field of cardiovascular diseases. It welcomes companies and institutions that can complement its existing expertise in artificial intelligence and mRNA technology and wish to actively contribute to the success of the cluster.

The curATime cluster aims to develop the next generation of medical solutions and revolutionise patient care!
Contact them for more information:

curatime@tron-mainz.de
curATime Cluster – Werden Sie Partner!Download

Our latest News

discover more
SPT Labtech and EMBL GeneCore Collaborate to Advance Fully Walkaway Automation in Genomics Workflows

SPT Labtech and EMBL GeneCore Collaborate to Advance Fully Walkaway Automation in Genomics Workflows

Cambridge, UK, and Heidelberg, Germany, 13 April 2026: SPT Labtech, a global leader in the design and development of laboratory automation and liquid handling solutions, and the European Molecular Biology Laboratory’s Genomics Core Facility (EMBL GeneCore), today announced a collaboration to advance fully walkaway automated genomics workflows. As part of the collaboration, SPT Labtech’s firefly®+ […]

read more
AskBio’s Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s Disease

AskBio’s Viralgen to Supply Commercial-Scale Drug Product for REGENERATE-PD Investigational Gene Therapy Phase II Trial for Parkinson’s Disease

Ametefgene parvec (AB-1005) manufactured at Viralgen commercial manufacturing facility with next-generation process to deliver high-purity product with greater efficiency Berlin, Germany, and Durham, N.C., USA, April 20, 2026 – AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that it has introduced its proprietary, commercially ready […]

read more
Molecular signature linked to aggressive growth of head and neck tumors discovered

Molecular signature linked to aggressive growth of head and neck tumors discovered

Researchers from Heidelberg University’s Faculty of Medicine and the Technical University of Munich have investigated the genetic activity of “budding” head and neck carcinomas. In the “buds”—clusters of cells that detach from the tumor and are associated with a poor prognosis—they found a characteristic pattern of gene activity. This marker signature provides insights into the […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp